138 related articles for article (PubMed ID: 17937927)
1. A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A.
Zaidi N; Burster T; Sommandas V; Herrmann T; Boehm BO; Driessen C; Voelter W; Kalbacher H
Biochem Biophys Res Commun; 2007 Dec; 364(2):243-9. PubMed ID: 17937927
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin E regulates the presentation of tetanus toxin C-fragment in PMA activated primary human B cells.
Burster T; Reich M; Zaidi N; Voelter W; Boehm BO; Kalbacher H
Biochem Biophys Res Commun; 2008 Dec; 377(4):1299-303. PubMed ID: 18996084
[TBL] [Abstract][Full Text] [Related]
3. Mannose-pepstatin conjugates as targeted inhibitors of antigen processing.
Free P; Hurley CA; Kageyama T; Chain BM; Tabor AB
Org Biomol Chem; 2006 May; 4(9):1817-30. PubMed ID: 16633575
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of antigen processing inhibitors to antigen presenting cells via mannose receptors.
Raiber EA; Tulone C; Zhang Y; Martinez-Pomares L; Steed E; Sponaas AM; Langhorne J; Noursadeghi M; Chain BM; Tabor AB
ACS Chem Biol; 2010 May; 5(5):461-476. PubMed ID: 20349916
[TBL] [Abstract][Full Text] [Related]
5. Application of specific cell permeable cathepsin G inhibitors resulted in reduced antigen processing in primary dendritic cells.
Reich M; Lesner A; Legowska A; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
Mol Immunol; 2009 Sep; 46(15):2994-9. PubMed ID: 19615749
[TBL] [Abstract][Full Text] [Related]
6. Pepstatin A-sensitive aspartic proteases in lysosome are involved in degradation of the invariant chain and antigen-processing in antigen presenting cells of mice infected with Leishmania major.
Zhang T; Maekawa Y; Yasutomo K; Ishikawa H; Fawzy Nashed B; Dainichi T; Hisaeda H; Sakai T; Kasai M; Mizuochi T; Asao T; Katunuma N; Himeno K
Biochem Biophys Res Commun; 2000 Sep; 276(2):693-701. PubMed ID: 11027533
[TBL] [Abstract][Full Text] [Related]
7. Replacement of isobutyl by trifluoromethyl in pepstatin A selectively affects inhibition of aspartic proteinases.
Binkert C; Frigerio M; Jones A; Meyer S; Pesenti C; Prade L; Viani F; Zanda M
Chembiochem; 2006 Jan; 7(1):181-6. PubMed ID: 16307463
[TBL] [Abstract][Full Text] [Related]
8. Pepstatin A, an aspartic proteinase inhibitor, suppresses RANKL-induced osteoclast differentiation.
Yoshida H; Okamoto K; Iwamoto T; Sakai E; Kanaoka K; Hu JP; Shibata M; Hotokezaka H; Nishishita K; Mizuno A; Kato Y
J Biochem; 2006 Mar; 139(3):583-90. PubMed ID: 16567424
[TBL] [Abstract][Full Text] [Related]
9. The expression and function of cathepsin E in dendritic cells.
Chain BM; Free P; Medd P; Swetman C; Tabor AB; Terrazzini N
J Immunol; 2005 Feb; 174(4):1791-800. PubMed ID: 15699105
[TBL] [Abstract][Full Text] [Related]
10. Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin.
Parikh S; Liu J; Sijwali P; Gut J; Goldberg DE; Rosenthal PJ
Antimicrob Agents Chemother; 2006 Jun; 50(6):2207-9. PubMed ID: 16723585
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of aspartic proteases by pepstatin and 3-methylstatine derivatives of pepstatin. Evidence for collected-substrate enzyme inhibition.
Rich DH; Bernatowicz MS; Agarwal NS; Kawai M; Salituro FG; Schmidt PG
Biochemistry; 1985 Jun; 24(13):3165-73. PubMed ID: 3927973
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases.
Ghittoni R; Napolitani G; Benati D; Ulivieri C; Patrussi L; Laghi Pasini F; Lanzavecchia A; Baldari CT
Eur J Immunol; 2006 Nov; 36(11):2885-93. PubMed ID: 17048274
[TBL] [Abstract][Full Text] [Related]
13. Pepstatin A induces extracellular acidification distinct from aspartic protease inhibition in microglial cell lines.
Okada M; Irie S; Sawada M; Urae R; Urae A; Iwata N; Ozaki N; Akazawa K; Nakanishi H
Glia; 2003 Aug; 43(2):167-74. PubMed ID: 12838508
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of pepstatin in cultured endothelial cells and its effect on endothelial processing.
Shields PP; Gonzales TA; Charles D; Gilligan JP; Stern W
Biochem Biophys Res Commun; 1991 Jun; 177(3):1006-12. PubMed ID: 2059194
[TBL] [Abstract][Full Text] [Related]
15. Biochemical characterization of an aspartic protease from Vigna radiata: Kinetic interactions with the classical inhibitor pepstatin implicating a tight binding mechanism.
Kulkarni A; Rao M
Biochim Biophys Acta; 2007 May; 1774(5):619-27. PubMed ID: 17478131
[TBL] [Abstract][Full Text] [Related]
16. Biological activity of aspartic proteinase inhibitors related to pepstatin.
Gunn JM; Owens RA; Liu WS; Glover GI
Acta Biol Med Ger; 1981; 40(10-11):1547-53. PubMed ID: 6805191
[TBL] [Abstract][Full Text] [Related]
17. Crystal structures of Aspergillus oryzae aspartic proteinase and its complex with an inhibitor pepstatin at 1.9A resolution.
Kamitori S; Ohtaki A; Ino H; Takeuchi M
J Mol Biol; 2003 Mar; 326(5):1503-11. PubMed ID: 12595261
[TBL] [Abstract][Full Text] [Related]
18. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.
Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW
Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050
[TBL] [Abstract][Full Text] [Related]
19. No role for pepstatin-A-sensitive acidic proteinases in reovirus infections of L or MDCK cells.
Kothandaraman S; Hebert MC; Raines RT; Nibert ML
Virology; 1998 Nov; 251(2):264-72. PubMed ID: 9837790
[TBL] [Abstract][Full Text] [Related]
20. Lower homologues of ahpatinin, aspartic protease inhibitors, from a marine Streptomyces sp.
Sun Y; Takada K; Nogi Y; Okada S; Matsunaga S
J Nat Prod; 2014 Jul; 77(7):1749-52. PubMed ID: 24960234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
